Pfizer presented updated clinical data supporting monthly dosing of berobenatide for obesity, following earlier signals from VESPER-3. In the study, patients transitioned from weekly dosing to higher monthly doses, with weight loss continuing through 28 weeks for those who stayed on treatment—an effort to compete with the growing set of weekly injectables and oral options.